anti-pd-1

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).

Anti-PD-1 Antibody (8P789) is a mouse (varialbe region) human (kappa IgG1 constant) chimeric monoclonal antibody targeting Human PD-1.

RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1 PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.

Anti-MousePD-1Antibody (J43) is an IgG antibody derived from mice, targeting PD-1 and originating from American hamsters. The isotype control for Anti-MousePD-1Antibody (J43) is Armenian hamsterIgG, Isotype Control.

The Anti-MousePD-1Antibody (29F.1A12) is an antibody derived from rat IgG2akappa that targets PD-1 in mice. The isotype control for Anti-MousePD-1Antibody (29F.1A12) is RatIgG2akappa, Isotype Control.

Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.

Anti-Mouse Human phosphorylated PD-1 CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1 CD279 in both mice and humans.

Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.

Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.

Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.

Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1 PD-L1 pathway, serving as a checkpoint inhibitor. It is applicable in research on metastatic cancer and squamous cell skin cancer.

Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) with potential antitumor activity for the study of the anti-PD-1 inhibitor budigalimab in non-small cell lung cancer.

Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.

Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.

Tagitanlimab (HBM-9167), a humanized anti-PD-L1 antibody (IgG1κ type), selectively inhibits the PD-L1 and PD-1 interaction. It shows promise for investigation in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1] [2].

Gilvetmab, a potent caninized anti-PD-1 monoclonal antibody, effectively inhibits the interaction between PD-1 and its ligand PDL-1 [1].

Iparomlimab, an IgG4κ anti-human PD-1 CD279 PDCD1 antibody, additionally binds to the human monoclonal PSB103 γ4-chain, forming a dimer through disulfide linkage with the human monoclonal PSB103 κ-chain. It is utilized in oncology research [1].

Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody [1].

Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody used to study unresectable hepatocellular carcinoma (uHCC) and metastatic colorectal cancer.

Toripalimab, the first domestic anti-tumor PD-1 antibody in China, is a selective, recombinant, humanized monoclonal antibody that targets PD-1. By binding to PD-1, it inhibits interactions with its ligands, demonstrating primary anti-tumor efficacy in various tumors, including melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma, and urothelial carcinoma [1].

Opucolimab, an anti-PD-L1 recombinant human monoclonal antibody, has applications in synthesizing antibody-agent conjugates and is utilized in research targeting advanced solid tumors [1].